News Posts List
Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma
02/06/2013
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.
13-year-old tuberous sclerosis patient with renal cell carcinoma
02/05/2013
We report a 13-year-old white girl with epilepsy and hypopigmented skin lesions...
Cancer's caregiver crisis of control
02/05/2013
Life experience doesn't prepare you for cancer caregiving.
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival
02/05/2013
CUB domain-containing protein 1 (CDCP1) is a transmembrane protein that is highly expressed in stem cells and frequently overexpressed and tyrosine-phosphorylated in cancer. CDCP1 promotes cancer cell metastasis...
23andMe: Innovation in Metastatic Cancer Researc
02/05/2013
Genetics can sometimes explain why some people respond well to a drug whereas others may experience serious side effects. The InVite Study is a collaborative effort between 23andMe and Genentech to learn more about how genes influence response to bevacizumab (also known as Avastin®) in the treatment of locally recurrent or metastatic breast cancer, metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, or metastatic renal cell carcinoma.
Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma
02/05/2013
The activity of systemic agents after progression when using vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibition (TKI) and mammalian target of rapamycin (mTOR) inhibition in patients with metastatic renal cell carcinoma (mRCC) is poorly characterized.
Today is World Cancer Day!
02/04/2013
Cancer is a leading cause of death worldwide. In 2008, it was the cause of 7.6 million deaths globally, and it is estimated that a third of those deaths could have been avoidable with greater prevention, early detection and existing treatments.
NCI Ends Brash Foray Into the News Business
02/01/2013
Emails Tell the Story of the NCI Cancer Bulletin
Shrive Named 2013 Uplifting Athletes Rare Disease Champion Award winner.
02/01/2013
Shrive was one of seven finalists this year and becomes the fifth recipient of the award.
David's Clinical Trial Experience
02/01/2013
David participated in a Phase 2 clinical study that evaluated a personalized cancer immunotherapy in combination with a standard targeted drug therapy, sunitinib.
News Feed